middle.news
Lumos Diagnostics Secures US$317M Deal, Awaits FDA Nod on FebriDx®
8:42am on Thursday 23rd of October, 2025 AEDT
•
Healthcare
Read Story
Lumos Diagnostics Secures US$317M Deal, Awaits FDA Nod on FebriDx®
8:42am on Thursday 23rd of October, 2025 AEDT
Key Points
US$3.4 million quarterly revenue, stable year-on-year
300% increase in product revenue led by FebriDx®
US$317 million exclusive U.S. distribution deal with PHASE Scientific
CLIA waiver application submitted to FDA, decision expected Nov 2025–Feb 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE